Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing ...
RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price targ...
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 GAAP EPS guidance from $(9.25)-$(7.50) to $(7.10)-$(5.20) vs $(7.76) analyst e...
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 Adj EPS guidance from $4.80-$5.60 to $7.65-$8.45 vs $5.33 analyst estimate. Na...
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $8.13 per share which beat the analyst consensus estimate of ...
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target fro...
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...
